Introduction
Community-acquired pneumonia (CAP) is the most common infection leading to hospitalization in the USA [1] and accounts for a substantial amount of antibiotic use. Ensuring optimal antibiotic prescribing for common infections is of fundamental importance to antibiotic stewardship efforts aimed at conserving currently licensed agents for as long as possible. Furthermore, attention to effective use of healthcare resources for common medical conditions, such as inpatient CAP, may help control rising healthcare costs while maintaining a high quality of care [2] .
Adherence to treatment recommendations in the 2007 Infectious Diseases Society of America (IDSA) and American Thoracic Society (ATS) guideline for the management of CAP has been associated with reduced mortality and length of hospital stay [3] . In addition, local guidelines and other antimicrobial stewardship interventions have successfully improved the care of patients hospitalized with CAP [4] [5] [6] [7] . However, before such interventions can be developed and implemented at a given institution, an in-depth understanding of management practices in relation to national guideline recommendations and quality measures is essential. We previously published an evaluation of antibiotic prescribing practices in cases of outpatient CAP that demonstrated frequent discordance with treatments suggested in the 2007 IDSA/ATS guideline [8] . The objective of this study was to perform a systematic and comprehensive assessment of management practices for patients hospitalized with CAP in relation to IDSA/ATS guideline recommendations in order to identify institutional targets for better antibiotic and healthcare resource stewardship.
Methods

Study setting and population
Denver Health is a vertically-integrated public safety net institution. Patients can access care at multiple sites, including a 477-bed teaching hospital, emergency department, urgent care center, community health centers, subspecialty clinics, and the public health department [9] . These sites are linked by a computerized health information system. Patients hospitalized with CAP are managed in medical wards [non-intensive care unit (ICU) cases] or in an ICU. Non-ICU cases are managed by either a housestaff teaching service or a hospitalist non-teaching service. The ICU is a closed-management academic model staffed by five critical care physicians.
Study design
We performed a retrospective cohort study of consecutive adults at least 18 years of age who had been hospitalized with CAP between 15 April 2008 and 31 May 2009. Eligible patients were identified using International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) criteria proposed by the Centers for Medicare and Medicaid Services (CMS) for inpatient pneumonia quality measures [10] . A manual chart review was then performed to identify cases meeting the study definition of CAP. Cases were excluded that did not meet this definition or that involved transfer from another facility, leaving against medical advice, presence of a co-existing infection requiring antibiotic therapy, age [89 years, incorrect ICD-9-CM code, missing records, not principal diagnosis, prisoner status, pregnancy, Pneumocystis jirovecii pneumonia, or mycobacterial infection. For patients with multiple hospitalizations at Denver Health for pneumonia during the study period, only the initial episode was reviewed.
Demographics, selected clinical characteristics, laboratory data, inpatient antibiotic administration, and selected clinical outcomes were extracted electronically via our healthcare data warehouse. Using a standardized data collection instrument, we performed manual chart abstraction for variables not available through the warehouse and to validate electronically obtained data (TJ, SS, LC). All clinical encounters occurring within 30 days after hospital discharge were reviewed to determine clinical outcomes. Prior to the study, the three abstractors performed chart review on ten pilot cases; discrepancies were reviewed and reconciled in order to decrease variability in the review process. A sample of abstraction forms was compared with the final database to ensure the accuracy of data entry. The study was reviewed by the Colorado Multiple Institutional Review Board and deemed to represent quality-improvement work.
Study definitions
Community-acquired pneumonia was defined as: (1) a new infiltrate based on chest radiograph or computed tomography (CT) scan within 48 h of hospital admission, (2) signs or symptoms of pneumonia not thought to be due to an alternative etiology, and (3) patient not hospitalized within 90 days, resident of a nursing facility, dialysis dependent, or having received parenteral antibiotic therapy, chemotherapy, or wound care within 30 days [11, 12] . Comorbid conditions were defined by provider diagnosis in the medical record. Severity of illness was determined with the CURB-65 score (confusion, uremia, respiratory rate, low blood pressure, age C65 years) as previously described [13] . Prolonged antibiotic therapy was defined as C10 days of treatment.
Use of chest CT was classified as early when obtained within 1 day of hospital admission. An expectorated sputum for Gram stain and culture was classified as an adequate sample when microscopy revealed \10 epithelial cells and [25 polymorphonuclear cells per high power field. The time to sputum culture was defined as the interval from the first dose of antibiotic to the first sample collected. Relevant pathogens were considered to be microorganisms known to cause pneumonia cultured from blood or pleural fluid, present in [10 5 colonies per milliliter by quantitative bronchoalveolar lavage (BAL) culture, or pure growth from an expectorated sputum or qualitative BAL specimen.
Clinical failure was a composite endpoint of any of the following during the hospitalization or 30-day follow-up period: (1) treatment failure, defined as a change in antibiotic therapy due to worsening signs or symptoms of infection or lack of clinical improvement, (2) in-hospital mortality, (3) recurrence, defined as signs or symptoms of infection after completion of therapy requiring re-initiation of antibiotics, (4) re-hospitalization due to pulmonary infection, or (5) death during the follow-up period.
Data analysis
Given expected differences in the evaluation, treatment, and outcomes of cases depending on severity of illness, analyses were performed both for the total cohort and stratified by non-ICU cases and ICU cases. Descriptive statistics were used to summarize demographic and clinical characteristics, use of microbiological and imaging studies, antibiotic treatment, and clinical outcomes. We performed multiple logistic regression using stepwise selection to assess factors associated with prolonged antibiotic therapy (C10 days). To do this, all potential factors were included in a full model for univariate analysis regardless of p value. The Akaike information criterion and the Bayesian information criterion were subsequently used to evaluate the goodness-of-fit of potential adjusted models. Variables were included in the final adjusted model based on goodness-of-fit, potential confounders, and collinearity with other factors. A p value of \0.05 was considered to be statistically significant. We used SAS ver. 9.2 software (SAS Institute, Cary, NC) for data analysis.
Results
A total of 391 eligible cases were identified with the initial ICD-9-CM search. Of these, 182 cases were excluded for reasons shown in Fig. 1 Table 1 ). The CURB-65 score was 0 or 1 in the majority of cases (137, 66 %); 61 (29 %) had a score of 0 or 1 and absence of a new oxygen requirement.
Chest CT scan was performed in 99 (47 %) cases ( Table 2) ; 59 (60 %) of these were pulmonary embolism protocol studies. Most were obtained early in the course of hospitalization (90/99, 91 %) and when an infiltrate was found to be present by plain film (54, 55 %). Blood cultures were ordered routinely for both non-ICU (81 %) and ICU (95 %) cases; however, 15 of 36 (42 %) positive cultures were false-positive results, including coagulasenegative staphylococci (13) , bacillus species, not anthracis (1), and enterococcus species (1) . Streptococcus pneumoniae was the infecting pathogen in 17 of 21 (81 %) cases with true bacteremia. Culture of an expectorated sputum was ordered in 110 (53 %) cases; however, an adequate specimen was obtained in only 49 (45 %) of such cases. The median time to collection was 11 h [interquartile range (IQR) [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , and a pathogen was identified in only 18 (16 %) cases. In total, a pathogen was identified by any microbiological test in 36 (17 %) of 209 cases, with S. pneumoniae being the most common pathogen identified (25, 12 %). Microbiological testing was less likely to yield a pathogen in non-ICU (17, 10 %) than in ICU cases (19, 44 %) (p \ 0.001).
The most frequently prescribed antibiotic regimen during the hospital stay was ceftriaxone ? azithromycin, administered in 147 (89 %) non-ICU cases and 35 (81 %) ICU cases ( Table 3 ). Use of anti-pseudomonal beta-lactam agents and vancomycin was more common in ICU cases (p \ 0.001 for both). In total, 53 (25 %) patients received at least one dose of vancomycin (median duration 2 days, IQR 1-4 days). Of the 182 patients treated with ceftriaxone ? azithromycin during hospitalization, 120 (66 %) were discharged on a new drug class, most commonly levofloxacin (101, 55 %). The median duration of therapy was 10 days for both non-ICU (IQR 8-14) and ICU (IQR 8-12) cases. Therapy was prolonged (C10 days) in 117 (56 %) cases. In multivariate logistic regression, bacteremia was the only factor independently associated with prolonged therapy [odds ratio (OR) 12.9, 95 % confidence interval (CI) 1.1-157.9] while discharge with azithromycin monotherapy (OR 0.02, 95 % CI 0.001-0.2) and cardiovascular disease (OR 0.3, 95 % CI 0.1-0.8) were inversely associated with prolonged therapy (Table 4 ). A summary of management practices compared with IDSA/ATS guideline recommendations is provided in Table 5 .
In total, clinical failure occurred in 19 (9 %) cases and was somewhat less frequent in non-ICU (7 %) than in ICU (16 %) cases (p = 0.07) ( Table 6 ). In-hospital failure events (treatment failure or death) tended to be more common than adverse outcomes after discharge (rehospitalization due to pulmonary infection, recurrence, or death within 30 days).
Discussion
Community-acquired pneumonia is the most common infection leading to hospitalization in the USA. In this cohort of inpatients with CAP, local clinical practice differed from IDSA/ATS guideline recommendations with respect to the decision to hospitalize, microbiological testing, oral antibiotic selection, and duration of therapy.
There is a large body of literature describing the diagnosis and treatment of inpatient CAP, and previous studies have identified opportunities and interventions to improve antibiotic prescribing and use of healthcare resources [4] [5] [6] [7] [14] [15] [16] [17] . Our study is unique in that it provides a model for a global assessment of management practices in comparison with national guideline recommendations, allowing individual hospitals to identify aspects of care that may warrant dedication of resources for quality improvement.
The IDSA/ATS guideline recommends the use of a severity-of-illness score, such as CURB-65, to assist in the decision to hospitalize or treat as an outpatient [11] . Patients with a CURB-65 score of 0 or 1 have a low risk of adverse outcomes and are generally recommended for outpatient therapy [13] . This severity of illness indicator was not routinely used in our emergency department during the study period, and the majority of patients hospitalized with CAP had a score or 0 or 1. Moreover, nearly 30 % had both a low CURB-65 score and absence of a new oxygen requirement, a marker of severity of illness that the (14) Prior pneumonia 24 (14) 4 (9) 28 (13) Cardiovascular disease a 20 (12) 6 (14) 26 (12) HIV infection 11 (7) 1 (2) 12 (6) Cirrhosis 7 (4) 3 (7) 10 (5) Injection drug use 5 (3) 3 (7) 8 (4) Failed outpatient antibiotic therapy 17 (10) 0 (0) 17 (8) CURB-65 score 0 55 (33) 4 (9) 59 (28) CURB-65 score does not take into account [18] . Although social factors and/or comorbid conditions likely influenced the decision to hospitalize in some cases [19] , admission may have been avoided in at least a subset of patients by using the CURB-65 score as an adjunct in the decisionmaking process.
The observation that CT scans were performed in close to half of cases and nearly always within 1 day of admission is noteworthy, and a similar frequent use of chest CT has been described previously [20] . Although the role of CT in the initial evaluation of CAP has not been clearly defined, plain films remain the standard of care for the diagnosis [21] . CT may be useful to evaluate for an alternative etiology when the diagnosis remains in question (e.g., pulmonary embolus) or for a specific complication of CAP (e.g., loculated pleural effusion). However, in our cohort, evidence of pneumonia was present by plain film in most cases where a CT was obtained. Furthermore, the early use of CT (most commonly in the emergency department) is suggestive of a use for diagnostic purposes rather than evaluation for complications. This study was not designed to assess the appropriateness of CT use, but given the expense and growing body of evidence of longterm risk of malignancy associated with radiation exposure from CT [22] , this is an area that requires further study. In the meantime, efforts should focus on ensuring an appropriate indication for chest CT in the setting of CAP to improve patient safety and control costs.
The utility of blood cultures for patients hospitalized with CAP is controversial [23, 24] . The IDSA/ATS guideline advocates for their use in critically ill patients and those with certain clinical factors or comorbidities. CMS requires blood cultures for ICU cases but has made them optional for non-ICU cases [10] . In our cohort, blood cultures were obtained in the majority of all admissions; the rate of 81 % we observed in non-ICU cases was more consistent with routine use rather than the targeted use as suggested in the guideline. We demonstrated an unintended consequence of such routine use of blood cultures in the non-ICU setting as 12 of 21 (57 %) positive cultures were false-positive results. Since falsepositive blood cultures lead to unnecessary antibiotic therapy, increased length of stay, and expense [25, 26] , this potential for misinformation is an important consideration in developing local strategies for use of blood cultures in CAP. The utility of Gram stain and culture of expectorated sputum is also controversial [27] . Sputum cultures were ordered in over half of cases; however, similar to a prior study [17] , a sample was not able to be obtained or was not adequate for evaluation the majority of the time. Furthermore, time delays in specimen collection contributed to a particularly low yield of pathogens for this test, especially in non-ICU cases. To summarize, we observed routine use of blood cultures in non-ICU patients, frequent falsepositive blood cultures, and poor yield of expectorated sputum cultures due to inadequate samples and time delays. Although we certainly recognize the importance and value of obtaining high-quality microbiological samples for culture in the appropriate clinical setting, our findings reveal several areas where use of these resources could be improved.
We identified three common prescribing practices for inpatient CAP that likely contribute to unnecessary antibiotic exposure: (1) frequent use of vancomycin, (2) transition to a new drug class for oral step-down therapy, and (3) use of a longer treatment duration than is likely necessary according to the IDSA/ATS guideline. First, we were surprised to find that one-quarter of patients were treated with vancomycin. Although some use was associated with false-positive blood cultures (prior to speciation of coagulase-negative staphylococci), most cases did not involve positive blood cultures, suggesting that vancomycin was added due to concern of methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. However, MRSA was identified in only three patients (1.4 %), a finding consistent with a recent epidemiological study of CAP in the USA [28] . Clinical features associated with MRSA pneumonia described in the study by Moran and colleagues [28] may be useful to provide specific guidance regarding when to empirically cover for MRSA and reduce what appears to be ''vancomycin creep'' into CAP therapy. The IDSA/ATS guideline recommends that when converting to oral therapy either the same agent or the same drug class should be used, and that switching to a different class due to high bioavailability (such as a fluoroquinolone) is generally not indicated. When an intravenous b-lactam/ macrolide combination is initially used, step-down therapy with an oral macrolide alone is suggested [11] . Inconsistent with this guidance, we found that two-thirds of patients initially treated with ceftriaxone ? azithromycin were transitioned to a new antibiotic class upon discharge, most often a respiratory fluoroquinolone. Given the association between fluoroquinolone exposure and both antimicrobial resistance [29] [30] [31] and severe Clostridium difficile infection [32] [33] [34] , this practice may put patients at unnecessary risk. In addition, since fluoroquinolones have activity against Mycobacterium tuberculosis, their use for CAP has resulted in delayed diagnosis and resistance in cases of tuberculosis [35, 36] . For these reasons, we agree with those who have advocated for more selective use of fluoroquinolones in CAP [35, 37, 38] and believe that preventing the switch to this drug class for oral step-down therapy is an appropriate initial step to decrease use.
A number of studies have demonstrated that treatment courses of fewer than 7 days are effective for inpatient CAP [39] . In one study of patients hospitalized with moderate to severe CAP, of whom 12 % were bacteremic, 3 days of therapy was as efficacious as 8 days [14] .
However, we found that 10-to 14-day courses (or longer) were prescribed in well over half of cases. By multivariate analysis, there was a notable absence of clinical factors positively associated with prolonged treatment (with the exception of bacteremia), reflecting the widespread nature of this prescribing practice. Of note, total and risk-adjusted antibiotic use at our hospital has been among the lowest in studies of academic hospitals [40, 41] , suggesting that these prolonged treatment durations are not unique to our institution. At least one other institution has described similar practice [5] . The growing body of evidence regarding the effectiveness of short-course therapy as well as the risk of C. difficile infection and other adverse events associated with longer courses of therapy [32, 42] suggest an important opportunity to reduce antibiotic exposure for CAP while improving patient safety. Currently, we advocate 5-day treatment courses for clinically responding patients. We agree with others who have suggested duration of therapy as a potential future CMS performance measure [5] .
This study has several limitations. First, it was performed at a single institution, and the results may not be generalizable. Being a U.S. hospital, we used the IDSA/ ATS guideline for reference, which has importance differences with respect to diagnostic and treatment recommendations as compared with European guidance [43] . Second, this was a retrospective study. Clinical failure events occurring after hospital discharge may have been missed. However, to minimize the potential for reviewer bias associated with this study design, we captured data electronically when possible. In addition, our study was largely descriptive and focused on objective hospital data, such as use of diagnostic tests and antibiotics. We therefore doubt reviewer bias had a significant impact on the results. Third, our microbiological data underrepresent organisms such as Mycoplasma, Chlamydia, and Legionella species for which testing is not routinely performed and microaerophilic streptococci and anaerobic organisms that can cause pneumonia [44] but are identified as normal oral flora by sputum culture. Conversely, growth of S. aureus or Gram-negative organisms in sputum culture often represent false-positive results [45] . Fourth, we did not assess the appropriateness of the decision to hospitalize, use of imaging studies or microbiological tests, and antibiotic therapy for individual cases. Therefore, we cannot conclude with certainty that the use of any of these resources was unnecessary. Last, the sample size precluded analysis of factors associated with adverse outcomes.
In summary, a detailed assessment of management practices for inpatient CAP compared with IDSA/ATS guideline recommendations revealed multiple opportunities for antibiotic and healthcare resource stewardship through reducing hospitalizations of low-risk patients, Data are presented as number (n) with the percentage in parenthesis unless otherwise noted ICU intensive care unit more appropriate use of microbiological tests, preventing antibiotic class-switching when transitioning to oral therapy, and shortening the duration of therapy. This model of a needs assessment could be used by other hospitals and antimicrobial stewardship programs to identify focus areas for quality improvement. A subsequent intervention involving a local guideline, peer champion advocacy, information technology, and clinician education could reduce antibiotic exposure, decrease healthcare costs, and improve patient safety.
